NYSEAMERICAN:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.44 +0.01 (+3.25%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartSEC FilingsShort InterestBuy This Stock About IGC Pharma Stock (NYSEAMERICAN:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.44▼$0.4650-Day Range N/A52-Week Range$0.25▼$0.50Volume1.03 million shsAverage Volume1.31 million shsMarket Capitalization$40.41 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company Overview IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. Read More IGC Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 1 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 6.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.21% of the outstanding shares of IGC Pharma have been sold short.Short Interest Ratio / Days to CoverIGC Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGC Pharma has recently decreased by 17.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.21% of the outstanding shares of IGC Pharma have been sold short.Short Interest Ratio / Days to CoverIGC Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IGC Pharma has recently decreased by 17.29%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentIGC Pharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.56 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 1 news article for IGC Pharma this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IGC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IGC Stock News HeadlinesAscendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEAMERICAN:IGC) StockAugust 27, 2025 | americanbankingnews.comSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.39 at the beginning of 2025. Since then, IGC shares have increased by 14.1% and is now trading at $0.4450. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray Brands (TLRY), Cronos Group (CRON), Micron Technology (MU) and NewAge (NBEV). Company Calendar Today9/02/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:IGC CIK1326205 WebN/A Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Price Target for IGC Pharma$4.50 High Price Target$4.50 Low Price Target$4.50 Potential Upside/Downside+911.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.12 million Net Margins-478.82% Pretax Margin-477.92% Return on Equity-97.59% Return on Assets-70.33% Debt Debt-to-Equity Ratio0.02 Current Ratio1.25 Quick Ratio0.47 Sales & Book Value Annual Sales$1.27 million Price / Sales31.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book5.56Miscellaneous Outstanding Shares90,810,000Free Float69,324,000Market Cap$40.41 million OptionableN/A Beta1.08 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSEAMERICAN:IGC) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.